Surpass Evolve™: follow-up of early cases from multicentre experience

From LINNC Paris 2023, join Prof. Monika KILLER-OBERPFALZER and Dr. Patrick NICHOLSON as they capture the excitement of the Stryker symposium speaking about the latest clinical experience using the Surpass Evolve™ flow diverter. Dr. NICHOLSON has been involved from the first-in-human intervention to today’s long-term follow-up of those initial cases and he emphasized the Surpass Evolve™’s ease of use and the high-wired braided design of the stent which he sees as providing better clinical and angiographic outcomes.

With precise deployment – avoiding the need to “drag and drop” that was often the case in earlier flow diverters – Prof. KILLER-OBERPFALZER and Dr. NICHOLSON offer specific clinical examples of Surpass Evolve™’s ability to avoid covering the wrong artery or angiographic outcomes of this flow diverter that translate into improved clinical outcomes in terms of aneurysm occlusion rates. The new architecture of the Surpass Evolve™ is proving safe and efficacious, demonstrating excellent clinical results such as better flow diversion and with a variety of sizes – including very large diameters and long stents – the Surpass Evolve™ can be “very useful in challenging giant aneurysms”. The Surpass Evolve™ also has no coating or surface modeling but has not shown to have higher thrombotic complications than other flow diverters.

What will the next generation of this device hold in store for the interventionists? How could this impact the duration of use of dual antiplatelet therapy?And with multicenter studies continuing, join us now to see where the Surpass Evolve™ platform is today, and stay tuned to LINNC and Stryker for future developments of this promising flow diverter.

Sponsored by Stryker

Видео Surpass Evolve™: follow-up of early cases from multicentre experience канала LINNC online